The prediction value of quantitative hepatitis B virus surface antigen and e antigen detections for pegylated interferon treatment of chronic hepatitis B
XIAO Hong1, ZHANG Wen-Hong2
1. Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China; 2. Huashan Hospital, Fudan University, Shanghai 200040, China
Abstract：Pegylated interferon (PEG-IFN) is the main measure of anti-hepatitis B virus (HBV) therapy. Compared with nucleotide drugs , PEG-IFN can achieve better immune control and higher serum conversion rates for both HBV surface antigen (HBsAg) and e antigen (HBeAg). With the development in sensitive assays for quantification of HBsAg and the study of natural history of HBV infection in recent years, studies demonstrated that there is a correlation between HBsAg level and both disease progression and host immune status. Recent studies have shown that HBsAg and HBeAg levels during anti-HBV therapy are closely related to sustained virologic response and could accurately predict the efficacy of treatment. Additional work is needed to standardize and validate these assays before they can be considered to be of true clinical applicability. The research progress in this area is reviewed in the present paper.
肖宏1，张文宏2. 乙型肝炎病毒表面抗原和e抗原定量检测对聚乙二醇干扰素治疗慢性乙型肝炎疗效的预测价值[J]. 微生物与感染
, 2012, 7(4): 255-259.
XIAO Hong1, ZHANG Wen-Hong2. The prediction value of quantitative hepatitis B virus surface antigen and e antigen detections for pegylated interferon treatment of chronic hepatitis B. Journal of Microbes and Infections, 2012, 7(4): 255-259.
